Marc Dunoyer (AstraZeneca via YouTube)

As­traZeneca shells out $775M to set­tle Ul­tomiris patent suit with Roche

A month af­ter re­ports first emerged that Roche and As­traZeneca have set­tled a years­long patent bat­tle over Ul­tomiris, we now know how much As­traZeneca paid to free it­self of the le­gal en­tan­gle­ments: $775 mil­lion.

Roche sub­sidiary Chugai first sued Alex­ion in 2018, be­fore Ul­tomiris was ap­proved and when it was still known as ravulizum­ab, al­leg­ing that Alex­ion used a Chugai tech­nol­o­gy in cre­at­ing the drug.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.